内科学
蛋白质组学
阿尔茨海默病
医学
荟萃分析
肿瘤科
载脂蛋白E
疾病
生物信息学
混淆
生物标志物
内分泌学
生物
生物化学
基因
作者
Siti Hajar Rehiman,Siong Meng Lim,Chin Fen Neoh,Abu Bakar Abdul Majeed,Ai‐Vyrn Chin,Maw Pin Tan,Shahrul Bahyah Kamaruzzaman,Kalavathy Ramasamy
标识
DOI:10.1016/j.arr.2020.101066
摘要
In order to gauge the impact of proteomics in discovery of Alzheimer’s disease (AD) blood-based biomarkers, this study had systematically reviewed articles published between 1984−2019. Articles that fulfilled the inclusion criteria were assessed for risk of bias. A meta-analysis was performed for replicable candidate biomarkers (CB). Of the 1651 articles that were identified, 17 case-control and two cohort studies, as well as three combined case-control and longitudinal designs were shortlisted. A total of 207 AD and mild cognitive impairment (MCI) CB were discovered, with 48 reported in >2 studies. This review highlights six CB, namely alpha-2-macroglobulin (α2M)ps, pancreatic polypeptide (PP)ps, apolipoprotein A-1 (ApoA-1)ps, afaminp, insulin growth factor binding protein-2 (IGFBP-2)ps and fibrinogen-γ-chainp, all of which exhibited consistent pattern of regulation in >three independent cohorts. They are involved in AD pathogenesis via amyloid-beta (Aβ), neurofibrillary tangles, diabetes and cardiovascular diseases (CVD). Meta-analysis indicated that ApoA-1ps was significantly downregulated in AD (SMD = −1.52, 95% CI: −1.89, −1.16, p < 0.00001), with low inter-study heterogeneity (I2 = 0%, p = 0.59). α2Mps was significantly upregulated in AD (SMD = 0.83, 95% CI: 0.05, 1.62, p = 0.04), with moderate inter-study heterogeneity (I2 = 41%, p = 0.19). Both CB are involved in Aβ formation. These findings provide important insights into blood-based AD biomarkers discovery via proteomics.
科研通智能强力驱动
Strongly Powered by AbleSci AI